Human papilloma virus (HPV) vaccination is associated with reduced number of surgical treatments, an observational study on recurrent respiratory papillomatosis in Northern Sweden

Abstract

Background

Recurrent respiratory papillomatosis (RRP) is a wart-like lesion mainly affecting the larynx, caused by human papillomavirus (HPV) genotypes 6 and 11. The disease affects both children and adults, and there is no cure. Surgery is the current symptom-relieving treatment; however, HPV vaccination is used as an adjuvant treatment.

Aims and Objectives

The aims were to study effects of HPV vaccination in RRP cases and to compare juvenile-onset to adult-onset disease and high treatment frequency (TF) to low TF cases.

Material and Methods

Medical records of RRP patients were studied from May 2006 to January 2023. Eighty-five RRP cases, tested for HPV genotypes with PapilloCheck®, were included. Vaccination- onset- and treatment analysis were performed.

Results

Twelve percent of the cases were vaccinated. The number of surgeries decreased from 2.0 to 0.8/year after HPV vaccination. Most cases had an adult-onset and less than one treatment per year. Juvenile-onset cases had a higher vaccination treatment ratio compared to adult-onset.

Conclusions

HPV vaccination was associated with a lower number of treatments per year, supporting the use of vaccination as an adjuvant treatment.

Significance

Vaccination as adjuvant treatment to surgery may lead to increased quality of life for RRP patients and saved healthcare resources.

Chinese Abstract

背景：复发性呼吸道乳头状瘤病（RRP）是一种主要影响喉部的疣样病变, 由人乳头瘤病毒 (HPV) 基因型 6 和 11 引起。该疾病影响儿童和成人, 并且没有治愈方法。 手术是目前缓解症状的治疗方法； 然而, HPV 疫苗接种被用作辅助治疗。

目的：研究 HPV 疫苗接种对 RRP 病例的影响, 并将青少年发病的疾病和成人发病的疾病以及高治疗频率 (TF) 病例和低 治疗频率病例进行比较。

材料和方法：研究了 2006 年 5 月至 2023 年 1 月 RRP 患者的医疗记录。纳入了 85 例 RRP 病例, 并使用 PapilloCheck® 进行了 HPV 基因型检测。 进行了疫苗接种、发病和治疗的分析。

结果：百分之十二的病例接种了疫苗。 手术数量从每年2.0次减少到接种 HPV 疫苗后每年 0.8 次。 大多数病例是成人发病, 每年治疗少于一次。与成人发病相比, 青少年发病病例的疫苗接种治疗率较高。

结论：HPV 疫苗接种与每年治疗次数较少相关, 支持使用疫苗接种作为辅助治疗。

意义：疫苗接种作为手术的辅助治疗可能会提高 RRP 患者的生活质量并节省医疗资源。

Keywords:

• Recurrent respiratory papillomatosis
• human papillomavirus viruses
• papillomavirus vaccines

Acknowledgments

We would like to thank PhD Anna Lindam for statistical advice and Professor Michael Haney for text revision.

Disclosure statement

No potential conflict of interest was reported by the author((s).

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request from other investigators adhering to the European Union General Data Protection Regulation (EU) 2016/679 GDPR.